Medical Director, Real-World Evidence Strategy

Alfasigma; Utrecht; Hybrid; EUR 170,000 - 210,000; Full time

Job summary

Alfasigma seeks a Medical Director, Evidence Generation, to drive strategic and operational activities of Medical Affairs through real world evidence generation. You will design studies, lead IEGPs, and collaborate across Medical Affairs, Publications, Pharmacovigilance, and Clinical Development to demonstrate product value.

The role emphasizes cross-functional leadership, regulatory compliance, and stakeholder engagement across the EU in a hybrid setup.

Qualifications

• Advanced degree and solid years of experience in evidence generation, HEOR, or related field.
• Experience designing and overseeing real-world evidence studies from protocol to delivery.
• Strong cross-functional collaboration across Medical Affairs, Publications, Pharmacovigilance, and Clinical Development.

Responsibilities

• Lead development and execution of Medical evidence generation strategy aligning with corporate goals and regional needs.
• Oversee Integrated Evidence Generation Plans (IEGPs) with clinical, real-world, and economic data.
• Provide epidemiological and HOR insights to brand teams and safety, and disseminate through reports and peer-reviewed publications.
• Ensure budgets, timelines and resources for evidence projects with quality and compliance.
• Foster a ONE Team culture and develop a high-performing Medical Affairs team.

Skills

Epidemiology

HEOR

RWE consulting

Project management

Stakeholder collaboration

Education

MD/PhD/PharmD or MPH/Health Economics

Job description

Alfasigma seeks a Medical Director, Evidence Generation, to drive strategic and operational activities of Medical Affairs through real world evidence generation. You will design studies, lead IEGPs, and collaborate across Medical Affairs, Publications, Pharmacovigilance, and Clinical Development to demonstrate product value.

The role emphasizes cross-functional leadership, regulatory compliance, and stakeholder engagement across the EU in a hybrid setup.